Rapamycin vs SS-31 (Elamipretide)
A side-by-side research comparison of Rapamycin and SS-31 (Elamipretide) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Rapamycin | SS-31 (Elamipretide) |
|---|---|---|
| Full name | Rapamycin (Sirolimus) | SS-31 / Elamipretide (Bendavia) |
| Category | Anti-Aging | Anti-Aging |
| Status | FDA-approved (off-label for longevity) | Investigational |
| Mechanism | Inhibits mTOR complex 1 (mTORC1), reducing cellular growth signaling and activating autophagy - the cellular recycling process. Mimics caloric restriction at the molecular level. | Targets cardiolipin in inner mitochondrial membrane, stabilizes cytochrome c binding, optimizes electron transfer efficiency, and reduces mitochondrial ROS by 50%. |
| Molecular weight | 914.17 Da | 640.8 Da |
| Half-life | ~62 hours | 4-6 hours |
| Bioavailability | ~14% oral | High (SubQ) |
| Typical dose | 3-6 mg | 5-40 mg |
| Frequency | Once weekly | Daily |
| Route | Oral tablet | Subcutaneous or IV |
Rapamycin reported benefits
- Enhanced autophagy
- Immune rejuvenation
- Anti-aging cellular effects
- Cancer risk reduction
- Improved vaccine response (elderly)
- Longevity extension
SS-31 (Elamipretide) reported benefits
- Mitochondrial function optimization
- Reduced oxidative stress
- Cardioprotection
- Improved exercise capacity
- Renal protection
- Cellular energy
Related comparisons
Research and educational reference only. Not medical advice.